To include your compound in the COVID-19 Resource Center, submit it here.

VGX-3400: Phase I data

An open-label, dose-escalation, U.S. and Korean Phase I trial in 60 healthy volunteers showed that

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE